Sawai Group Holdings Co., Ltd. (4887.T)
JPY 2038.0
(1.67%)
JPY 2038.0
(1.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 13.69 Billion JPY | 8.12% |
| 2022 | 12.66 Billion JPY | 144.81% |
| 2021 | -28.26 Billion JPY | -329.08% |
| 2020 | 12.34 Billion JPY | -35.99% |
| 2019 | 19.27 Billion JPY | -0.5% |
| 2018 | 19.37 Billion JPY | 38.23% |
| 2017 | 14.01 Billion JPY | -21.99% |
| 2016 | 17.96 Billion JPY | 4.74% |
| 2015 | 17.15 Billion JPY | 22.07% |
| 2014 | 14.05 Billion JPY | 15.26% |
| 2013 | 12.19 Billion JPY | 1.41% |
| 2012 | 12.02 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 15.48 Billion JPY | 7882.47% |
| 2023 FY | 13.69 Billion JPY | 8.12% |
| 2023 Q3 | 5.05 Billion JPY | 2.66% |
| 2023 Q4 | 194 Million JPY | -96.16% |
| 2023 Q1 | 3.51 Billion JPY | 93.08% |
| 2023 Q2 | 4.92 Billion JPY | 40.02% |
| 2022 Q4 | 1.82 Billion JPY | -56.46% |
| 2022 Q3 | 4.18 Billion JPY | 40.06% |
| 2022 Q2 | 2.98 Billion JPY | -18.63% |
| 2022 Q1 | 3.67 Billion JPY | 108.32% |
| 2022 FY | 12.66 Billion JPY | 144.81% |
| 2021 Q4 | -44.15 Billion JPY | -783.36% |
| 2021 Q1 | 6.3 Billion JPY | 224.94% |
| 2021 FY | -28.26 Billion JPY | -329.08% |
| 2021 Q3 | 6.46 Billion JPY | 107.48% |
| 2021 Q2 | 3.11 Billion JPY | -50.63% |
| 2020 Q3 | 6.58 Billion JPY | 23.62% |
| 2020 Q1 | 5.47 Billion JPY | 179.08% |
| 2020 FY | 12.34 Billion JPY | -35.99% |
| 2020 Q4 | -5.04 Billion JPY | -176.61% |
| 2020 Q2 | 5.33 Billion JPY | -2.56% |
| 2019 Q4 | 1.96 Billion JPY | -69.12% |
| 2019 Q3 | 6.34 Billion JPY | 39.93% |
| 2019 Q2 | 4.53 Billion JPY | -29.52% |
| 2019 FY | 19.27 Billion JPY | -0.5% |
| 2019 Q1 | 6.43 Billion JPY | 150.23% |
| 2018 Q2 | 5.25 Billion JPY | 0.02% |
| 2018 Q3 | 6.28 Billion JPY | 19.55% |
| 2018 Q1 | 5.25 Billion JPY | 19574.07% |
| 2018 FY | 19.37 Billion JPY | 38.23% |
| 2018 Q4 | 2.57 Billion JPY | -59.09% |
| 2017 FY | 14.01 Billion JPY | -21.99% |
| 2017 Q1 | 4.65 Billion JPY | 109.35% |
| 2017 Q4 | -27 Million JPY | -100.51% |
| 2017 Q3 | 5.25 Billion JPY | 27.04% |
| 2017 Q2 | 4.13 Billion JPY | -11.19% |
| 2016 Q2 | 4.2 Billion JPY | -3.42% |
| 2016 Q4 | 2.22 Billion JPY | -56.6% |
| 2016 Q1 | 4.35 Billion JPY | 38.32% |
| 2016 Q3 | 5.12 Billion JPY | 21.79% |
| 2016 FY | 17.96 Billion JPY | 4.74% |
| 2015 FY | 17.15 Billion JPY | 22.07% |
| 2015 Q4 | 3.15 Billion JPY | -42.8% |
| 2015 Q3 | 5.5 Billion JPY | 61.64% |
| 2015 Q2 | 3.4 Billion JPY | -33.08% |
| 2015 Q1 | 5.09 Billion JPY | 116.82% |
| 2014 Q4 | 2.34 Billion JPY | -50.13% |
| 2014 Q3 | 4.7 Billion JPY | 32.28% |
| 2014 Q2 | 3.55 Billion JPY | 3.52% |
| 2014 Q1 | 3.43 Billion JPY | 152.98% |
| 2014 FY | 14.05 Billion JPY | 15.26% |
| 2013 Q2 | 2.7 Billion JPY | -28.22% |
| 2013 Q1 | 3.77 Billion JPY | 72.62% |
| 2013 Q4 | 1.35 Billion JPY | -68.81% |
| 2013 FY | 12.19 Billion JPY | 1.41% |
| 2013 Q3 | 4.35 Billion JPY | 61.01% |
| 2012 Q4 | 2.18 Billion JPY | -49.98% |
| 2012 Q2 | 2.77 Billion JPY | 0.0% |
| 2012 FY | 12.02 Billion JPY | 0.0% |
| 2012 Q3 | 4.36 Billion JPY | 57.56% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | -327.301% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 90.494% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 104.348% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 91.548% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | -12468.948% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 47.023% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | -70.654% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 67.706% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | -1864.849% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 1.961% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | -201.188% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | -894.553% |
| Nippon Chemiphar Co., Ltd. | -180 Million JPY | 7708.333% |
| Tsumura & Co. | 16.7 Billion JPY | 18.028% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | -22.715% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | -232.484% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 15.322% |
| Fuji Pharma Co., Ltd. | 3.43 Billion JPY | -298.69% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | -77.138% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | -157.328% |
| Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 379.832% |
| Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | -315.63% |
| SymBio Pharmaceuticals Limited | -1.96 Billion JPY | 797.722% |
| MedRx Co., Ltd | -932 Million JPY | 1569.421% |
| Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | -262.855% |
| Solasia Pharma K.K. | -1.11 Billion JPY | 1331.565% |
| Modalis Therapeutics Corporation | -2.39 Billion JPY | 672.576% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | -81.511% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | 2424.295% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 33.703% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | -364.814% |